SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency.
SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency.
复制标题
一例X连锁重症联合免疫缺陷婴儿的SARS-CoV-2感染与肝炎相关
DOI：
10.1016/j.clim.2020.108662
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Wysocki CA
中科院分区：
文献类型：
--
作者：
van Oers NSC;Hanners NW;Sue PK;Aquino V;Li QZ;Schoggins JW;Wysocki CA
X连锁严重联合免疫缺陷症 (X-SCID) 是一种适应性免疫疾病，由 IL-2 受体共同伽马链基因突变导致 T 细胞和自然杀伤细胞缺陷，并伴有 B 细胞严重功能障碍。由于机会性感染，在没有同种异体干细胞移植或基因治疗的情况下，X-SCID 是致命的。一名患有 X-SCID 的婴儿在等待移植期间感染了 SARS-CoV-2。该患者出现严重肝炎，但没有出现 COVID-19 典型的呼吸道症状。他接受了恢复期血浆治疗，随后通过微流控抗原阵列检测，确认其体内存在 SARS-CoV-2 特异性抗体。肝炎痊愈后，他从已从 COVID-19 中康复的父亲处接受了半相合 CD34 选择干细胞移植，无需进行预处理。直到移植后 61 天，通过 RT-PCR 在鼻咽拭子上检测到 SARS CoV-2。他成功植入了供体 T 细胞和 NK 细胞，并继续在临床上表现出色。
X-linked severe combined immunodeficiency (X-SCID) is a disorder of adaptive immunity caused by mutations in the IL-2 receptor common gamma chain gene resulting in deficiencies of T and natural killer cells, coupled with severe dysfunction in B cells. X-SCID is lethal without allogeneic stem cell transplant or gene therapy due to opportunistic infections. An infant with X-SCID became infected with SARS-CoV-2 while awaiting transplant. The patient developed severe hepatitis without the respiratory symptoms typical of COVID-19. He was treated with convalescent plasma, and thereafter was confirmed to have SARS-CoV-2 specific antibodies, as detected with a microfluidic antigen array. After resolution of the hepatitis, he received a haploidentical CD34 selected stem cell transplant, without conditioning, from his father who had recovered from COVID-19. SARS CoV-2 was detected via RT-PCR on nasopharyngeal swabs until 61 days post transplantation. He successfully engrafted donor T and NK cells, and continues to do well clinically.
登录
查看更多内容
影响因子：
5.8
作者：
Peng, Hui;Yang, Li-tao;Wu, Chang-you
通讯作者：
Wu, Chang-you
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
影响因子：
5.4
作者：
Shirato, Kazuya;Kawase, Miyuki;Matsuyama, Shutoku
通讯作者：
Matsuyama, Shutoku
影响因子：
3.6
作者：
Lu, Yingying;Li, Yi;Du, Hao
通讯作者：
Du, Hao